Jacobio Pharmaceuticals Group Co., Ltd. repurchased 100,500 ordinary shares on 28 May 2026 through on-market transactions on the Hong Kong Stock Exchange, paying a total of HKD0.47 million at prices between HKD4.68 and HKD4.72 per share. The volume-weighted average purchase price was HKD4.71 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.01% to 784.06 million shares, while treasury shares increased to 7.69 million. Total issued shares remained unchanged at 791.76 million, as the repurchased stock is being held in treasury rather than cancelled.

The purchase forms part of the repurchase mandate approved on 10 June 2025, which authorises Jacobio Pharmaceuticals to buy back up to 78.87 million shares. Cumulative repurchases under this mandate have reached 4.67 million shares, equivalent to 0.59% of the company’s issued share capital on the mandate date. In line with Hong Kong listing rules, the company is subject to a moratorium on issuing or selling shares or transferring treasury shares until 27 June 2026.